Logo image of GRFS

GRIFOLS SA-ADR (GRFS) Stock Fundamental Analysis

NASDAQ:GRFS - Nasdaq - US3984384087 - ADR - Currency: USD

9.74  -0.01 (-0.1%)

After market: 9.74 0 (0%)

Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to GRFS. GRFS was compared to 557 industry peers in the Biotechnology industry. GRFS scores excellent on profitability, but there are some minor concerns on its financial health. GRFS scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

GRFS had positive earnings in the past year.
GRFS had a positive operating cash flow in the past year.
GRFS had positive earnings in each of the past 5 years.
In multiple years GRFS reported negative operating cash flow during the last 5 years.
GRFS Yearly Net Income VS EBIT VS OCF VS FCFGRFS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M 1B

1.2 Ratios

With an excellent Return On Assets value of 0.93%, GRFS belongs to the best of the industry, outperforming 90.48% of the companies in the same industry.
Looking at the Return On Equity, with a value of 3.46%, GRFS belongs to the top of the industry, outperforming 92.64% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 4.20%, GRFS belongs to the top of the industry, outperforming 92.82% of the companies in the same industry.
GRFS had an Average Return On Invested Capital over the past 3 years of 2.90%. This is significantly below the industry average of 14.78%.
The 3 year average ROIC (2.90%) for GRFS is below the current ROIC(4.20%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.93%
ROE 3.46%
ROIC 4.2%
ROA(3y)0.66%
ROA(5y)1.4%
ROE(3y)2.39%
ROE(5y)4.54%
ROIC(3y)2.9%
ROIC(5y)3.1%
GRFS Yearly ROA, ROE, ROICGRFS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

GRFS's Profit Margin of 2.65% is amongst the best of the industry. GRFS outperforms 91.38% of its industry peers.
GRFS's Profit Margin has declined in the last couple of years.
GRFS's Operating Margin of 16.65% is amongst the best of the industry. GRFS outperforms 95.15% of its industry peers.
GRFS's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 38.77%, GRFS is doing good in the industry, outperforming 74.69% of the companies in the same industry.
GRFS's Gross Margin has declined in the last couple of years.
Industry RankSector Rank
OM 16.65%
PM (TTM) 2.65%
GM 38.77%
OM growth 3Y11.99%
OM growth 5Y-6.16%
PM growth 3Y-17.15%
PM growth 5Y-29.24%
GM growth 3Y-0.88%
GM growth 5Y-3.34%
GRFS Yearly Profit, Operating, Gross MarginsGRFS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

More info and screens

4

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so GRFS is destroying value.
The number of shares outstanding for GRFS remains at a similar level compared to 1 year ago.
GRFS has about the same amout of shares outstanding than it did 5 years ago.
Compared to 1 year ago, GRFS has an improved debt to assets ratio.
GRFS Yearly Shares OutstandingGRFS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
GRFS Yearly Total Debt VS Total AssetsGRFS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

GRFS has an Altman-Z score of 1.25. This is a bad value and indicates that GRFS is not financially healthy and even has some risk of bankruptcy.
GRFS has a Altman-Z score of 1.25. This is in the better half of the industry: GRFS outperforms 66.07% of its industry peers.
GRFS has a debt to FCF ratio of 12.50. This is a negative value and a sign of low solvency as GRFS would need 12.50 years to pay back of all of its debts.
GRFS has a better Debt to FCF ratio (12.50) than 92.28% of its industry peers.
GRFS has a Debt/Equity ratio of 1.67. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of GRFS (1.67) is worse than 79.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.67
Debt/FCF 12.5
Altman-Z 1.25
ROIC/WACC0.71
WACC5.9%
GRFS Yearly LT Debt VS Equity VS FCFGRFS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B

2.3 Liquidity

GRFS has a Current Ratio of 2.60. This indicates that GRFS is financially healthy and has no problem in meeting its short term obligations.
GRFS's Current ratio of 2.60 is on the low side compared to the rest of the industry. GRFS is outperformed by 68.76% of its industry peers.
A Quick Ratio of 0.97 indicates that GRFS may have some problems paying its short term obligations.
With a Quick ratio value of 0.97, GRFS is not doing good in the industry: 86.89% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 0.97
GRFS Yearly Current Assets VS Current LiabilitesGRFS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

5

3. Growth

3.1 Past

GRFS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.72%, which is quite good.
The earnings per share for GRFS have been decreasing by -23.99% on average. This is quite bad
The Revenue has grown by 10.76% in the past year. This is quite good.
The Revenue has been growing slightly by 7.18% on average over the past years.
EPS 1Y (TTM)15.72%
EPS 3Y-6.22%
EPS 5Y-23.99%
EPS Q2Q%192.67%
Revenue 1Y (TTM)10.76%
Revenue growth 3Y13.5%
Revenue growth 5Y7.18%
Sales Q2Q%9.85%

3.2 Future

Based on estimates for the next years, GRFS will show a very strong growth in Earnings Per Share. The EPS will grow by 24.02% on average per year.
GRFS is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.48% yearly.
EPS Next Y42.14%
EPS Next 2Y37.01%
EPS Next 3Y30.46%
EPS Next 5Y24.02%
Revenue Next Year7.14%
Revenue Next 2Y7.15%
Revenue Next 3Y6.89%
Revenue Next 5Y5.48%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GRFS Yearly Revenue VS EstimatesGRFS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
GRFS Yearly EPS VS EstimatesGRFS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 28.65, GRFS can be considered very expensive at the moment.
94.43% of the companies in the same industry are more expensive than GRFS, based on the Price/Earnings ratio.
GRFS is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.47, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 8.05, which indicates a very decent valuation of GRFS.
Based on the Price/Forward Earnings ratio, GRFS is valued cheaply inside the industry as 97.49% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of GRFS to the average of the S&P500 Index (21.91), we can say GRFS is valued rather cheaply.
Industry RankSector Rank
PE 28.65
Fwd PE 8.05
GRFS Price Earnings VS Forward Price EarningsGRFS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, GRFS is valued cheaply inside the industry as 97.67% of the companies are valued more expensively.
98.38% of the companies in the same industry are more expensive than GRFS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 7.04
EV/EBITDA 8.64
GRFS Per share dataGRFS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of GRFS may justify a higher PE ratio.
A more expensive valuation may be justified as GRFS's earnings are expected to grow with 30.46% in the coming years.
PEG (NY)0.68
PEG (5Y)N/A
EPS Next 2Y37.01%
EPS Next 3Y30.46%

More info and screens

0

5. Dividend

5.1 Amount

GRFS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRIFOLS SA-ADR

NASDAQ:GRFS (7/11/2025, 4:30:01 PM)

After market: 9.74 0 (0%)

9.74

-0.01 (-0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12
Earnings (Next)07-29 2025-07-29
Inst Owners34.27%
Inst Owner Change0%
Ins Owners6.34%
Ins Owner ChangeN/A
Market Cap6.62B
Analysts73.68
Price Target12.85 (31.93%)
Short Float %0.98%
Short Ratio3.54
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)-66.87%
DP0.49%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.06%
PT rev (3m)-10.95%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.09%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.21%
Valuation
Industry RankSector Rank
PE 28.65
Fwd PE 8.05
P/S 0.77
P/FCF 7.04
P/OCF 4.7
P/B 1
P/tB N/A
EV/EBITDA 8.64
EPS(TTM)0.34
EY3.49%
EPS(NY)1.21
Fwd EY12.43%
FCF(TTM)1.38
FCFY14.21%
OCF(TTM)2.07
OCFY21.27%
SpS12.7
BVpS9.72
TBVpS-9.62
PEG (NY)0.68
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.93%
ROE 3.46%
ROCE 6.53%
ROIC 4.2%
ROICexc 4.43%
ROICexgc 12%
OM 16.65%
PM (TTM) 2.65%
GM 38.77%
FCFM 10.9%
ROA(3y)0.66%
ROA(5y)1.4%
ROE(3y)2.39%
ROE(5y)4.54%
ROIC(3y)2.9%
ROIC(5y)3.1%
ROICexc(3y)3.07%
ROICexc(5y)3.33%
ROICexgc(3y)6.89%
ROICexgc(5y)7.47%
ROCE(3y)4.51%
ROCE(5y)4.82%
ROICexcg growth 3Y11.6%
ROICexcg growth 5Y-8.62%
ROICexc growth 3Y14.21%
ROICexc growth 5Y-7.74%
OM growth 3Y11.99%
OM growth 5Y-6.16%
PM growth 3Y-17.15%
PM growth 5Y-29.24%
GM growth 3Y-0.88%
GM growth 5Y-3.34%
F-Score8
Asset Turnover0.35
Health
Industry RankSector Rank
Debt/Equity 1.67
Debt/FCF 12.5
Debt/EBITDA 5.62
Cap/Depr 89.85%
Cap/Sales 5.41%
Interest Coverage 250
Cash Conversion 71.93%
Profit Quality 411.63%
Current Ratio 2.6
Quick Ratio 0.97
Altman-Z 1.25
F-Score8
WACC5.9%
ROIC/WACC0.71
Cap/Depr(3y)62.1%
Cap/Depr(5y)77.33%
Cap/Sales(3y)1.39%
Cap/Sales(5y)3.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.72%
EPS 3Y-6.22%
EPS 5Y-23.99%
EPS Q2Q%192.67%
EPS Next Y42.14%
EPS Next 2Y37.01%
EPS Next 3Y30.46%
EPS Next 5Y24.02%
Revenue 1Y (TTM)10.76%
Revenue growth 3Y13.5%
Revenue growth 5Y7.18%
Sales Q2Q%9.85%
Revenue Next Year7.14%
Revenue Next 2Y7.15%
Revenue Next 3Y6.89%
Revenue Next 5Y5.48%
EBIT growth 1Y39%
EBIT growth 3Y27.11%
EBIT growth 5Y0.58%
EBIT Next Year53.59%
EBIT Next 3Y23.7%
EBIT Next 5Y14.42%
FCF growth 1Y-79.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.33%
OCF growth 3YN/A
OCF growth 5YN/A